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Clinical evidence suggests that the residual cardio-
vascular (CV) risk observed in patients with well-
controlled low-density lipoprotein cholesterol
(LDL-C) levels can be, in part, explained by residual
lipid risk factors, among which the cholesterol content
of remnants of triglyceride (TG)-rich lipoproteins
(TRLs) appears to play a key role.1 Observational
and genetic studies have shown that remnant choles-
terol (RC) is a causal risk factor for ischemic heart
disease,2 and more recently it has been associated also
with an increased risk of ischemic stroke.3 Indeed, sev-
eral studies have shown that non-high-density lipopro-
tein cholesterol (non-HDL-C) levels, which recapitulate
the cholesterol content of all atherogenic apolipopro-
tein B (apoB)-containing lipoproteins including rem-
nants, are a better predictor of CV risk than LDL-C
levels alone.4,5 In agreement with these observations,
Mendelian randomization studies have suggested that
the clinical benefit of lowering LDL-C may be better
explained by the absolute reduction in apoB-containing
lipoproteins.6,7
In their study, Elshazly et al. have evaluated whether
RC associates with coronary atheroma progression and
clinical events independently of LDL-C values in 5754
patients from 10 interventional trials.8 Despite an over-
all effective treatment resulting in robust reductions of
plasma lipids (including LDL-C, RC, TG, non-HDL-
C) and apoB levels, a variability in the response for
changes in the percent atheroma volume (PAV) was
observed.8 Of note, higher on-treatment RC levels
were significantly associated with a greater progression
of coronary atheroma, and also with an increased
cumulative incidence of major adverse CV events at
24 months.8 Atheroma progression occurred when on-
treatment RC levels were higher than 25–30mg/dL
(depending on the method used for LDL-C level esti-
mation), and was more strongly associated with
changes in RC than LDL-C or apoB levels.8 These
results seem to be in agreement with a recent study
demonstrating a relationship between RC and total
coronary atherosclerotic plaque burden (evaluated by
computed tomography coronary angiography) in a
population of patients with optimal LDL-C levels
(mostly treated with statins), in which RC levels
remained an independent predictor of coronary ath-
erosclerotic burden after adjusting for traditional risk
factors.9 In the GLAGOV study (included in the ana-
lysis of Elshazly et al.), only about two-thirds of
Evolocumab-treated patients achieved plaque regres-
sion, despite reaching very low levels of LDL-C.10
Although the possibility that the limited length of this
trial (78 weeks) explains this result, as the reduction of
plasma LDL-C levels does not immediately translate
into an effective decrease of cholesterol load within
the arteries, it also suggests that factors other than
LDL-C might contribute to the disease (and to the resi-
dual CV risk), including RC. In addition, the compos-
ition of atherosclerotic plaque, and more specifically its
lipid content, is a major determinant of the regression
process potentially induced by a lipid-lowering treat-
ment; indeed, a meta-analysis showed that high-inten-
sity statin therapy promotes coronary plaque
calcification rather than overall atheroma volume
regression.11
The mechanisms by which TRL remnants contribute
to the atherogenic process are not fully understood.
Due to their size, remnants can enter the subendothelial
space, where they are retained; of note, remnant lipo-
proteins carry significantly more cholesterol per particle
than LDL and do not require oxidation to be taken up
by macrophages; within the subendothelial space,
remnants induce a local low-grade inflammation,
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endothelial dysfunction, and foam cell formation, as it
occurs for LDL.1,12,13
The study by Elshazly et al. presents with some limi-
tations. The first is of methodological nature, as the
definition of RC is at the best approximate, since it
recapitulates the cholesterol present in circulating TG-
rich particles, mainly very low-density lipoprotein
(VLDL). Measuring remnants of chylomicrons and
VLDL (which represent variable fractions of the total
VLDL-cholesterol) is not something that is easily done
and certainly was not performed in the studies analysed
by the authors. Further, the observation that apoB is
outperformed by the cholesterol content of VLDL (as
in all trials patients with elevated TG were excluded
and samples were obtained in fasting conditions) is
rather surprising and may be related to the relatively
poor standardization of apoB determination versus
cholesterol evaluation.
That said, other points require further analyses: for
instance, whether subjects who had higher on-treatment
RC levels benefited differently from lipid-lowering.
Moreover, this analysis included studies evaluating
drugs targeting different CV risk factors, including
not only lipid-modifying drugs (statins, a cholesteryl
ester transfer protein (CETP) inhibitor and a propro-
tein convertase subtilisin/kexin type 9 inhibitor), but
also anti-hypertensive or anti-diabetics agents (which
are not reported to have significant effects on lipid
levels). All the studies testing the effect of non-statin
therapies on PAV progression had an elevated percent-
age of patients (>80%) on a background statin treat-
ment, and this could have affected the possibility to
appreciate changes in lipoprotein catabolism. Indeed,
while the emerging key message from the study is that
the reduction of LDL-C levels (23%) does not trans-
late in RC reduction (3%), the possibility that specific
trials might diverge from this picture and perhaps drive
the overall result is not discussed. In addition, for the
calculation of RC, in their analysis the authors esti-
mated LDL-C using the Hopkins–Martin equation,
instead of Friedewald’s8 (when TG levels were
<400mg/dL) – a comparison between these two
approaches would have been useful.
Taking into account these limitations, the multivari-
ate analysis showed that, after adjusting for several fac-
tors, including trial duration, baseline plaque atheroma
volume, C-reactive protein (CRP), on-treatment LDL-
C, and apoB levels, differences in on-treatment RC sur-
prisingly remained significantly associated to atheroma
progression.8 This is an unexpected finding as apoB,
per se, should better mirror the totality of atherogenic
lipoproteins. Indeed, a recent Mendelian randomiza-
tion study showed that TG-lowering variants in the
lipoprotein lipase gene and LDL-C-lowering variants
in the LDL receptor gene were associated with
comparable coronary heart disease (CHD) risk reduc-
tion per 10-mg/dL lower level of apoB-containing lipo-
proteins.7 The multivariable Mendelian randomization
analysis showed that the significant direct association
of TG and of LDL-C levels with CHD became null
after adjusting for apoB levels, suggesting that the clin-
ical benefit of lowering TG levels or LDL-C levels are
similar per unit change in apoB levels and likely asso-
ciated to the absolute reduction in apoB-containing
lipoprotein particles.7 On this premise, the data by
Elshazly et al. raise the question of whether measuring
RC levels provides superior information on the athero-
genic load of remnant particles beyond apoB determi-
nation. Changes in plaque composition and size may
not be, overall, related to the clinical events and this
may also explain the apparent divergent results.
Another point of discussion is the observation that,
in contrast with previous studies proposing that rem-
nant particles contribute to atherogenesis by inducing
low-grade inflammation,12,14 as well as endothelial dys-
function by promoting endothelial pro-inflammatory
activation and a reduced flow-mediated dilatation
both under fasting and post-prandial response,13,15
the study by Elshazly et al. showed that RC remains
an independent predictor of PAV progression even
after adjusting for CRP. This seems to suggest that
the deleterious effect of RC is independent of the sys-
temic inflammatory response as determined by CRP
(as observed also for LDL) and further raises questions
on the pathophysiological mechanisms triggered by
remnant particles. Are they supporting atherosclerosis
progression and vascular damage without activating
the inflammatory response via the classical inflamma-
some/IL-1ß/IL-18 pathway as it happens when choles-
terol crystals accumulate within macrophages? If this is
the case, is cholesterol carried by remnant particles
handled differently from that deriving from LDL par-
ticles within vascular wall cells? While further ad hoc
studies are needed to answer these questions, the work
by Elshazly et al. clearly represents a good example on
how the analysis of clinical data generates novel
hypotheses to be tested at the molecular and cellular
levels.
In conclusion, this work highlights how a residual
risk related to lipoprotein classes other than LDL per-
sists also in patients with baseline values for non-
LDL-C lipid variables, including plasma TG and
HDL-C, within what is regarded as a normal range;
however, it does not detract, as also stated by the
authors, from the benefits of lowering LDL-C.
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